Skip to main content
Top
Published in: Radiation Oncology 1/2017

Open Access 01-12-2017 | Research

Target volume delineation of anal cancer based on magnetic resonance imaging or positron emission tomography

Authors: Espen Rusten, Bernt Louni Rekstad, Christine Undseth, Ghazwan Al-Haidari, Bettina Hanekamp, Eivor Hernes, Taran Paulsen Hellebust, Eirik Malinen, Marianne Grønlie Guren

Published in: Radiation Oncology | Issue 1/2017

Login to get access

Abstract

Purpose

To compare target volume delineation of anal cancer using positron emission tomography (PET) and magnetic resonance imaging (MRI) with respect to inter-observer and inter-modality variability.

Methods

Nineteen patients with anal cancer undergoing chemoradiotherapy were prospectively included. Planning computed tomography (CT) images were co-registered with 18F–fluorodexocyglucose (FDG) PET/CT images and T2 and diffusion weighted (DW) MR images. Three oncologists delineated the Gross Tumor Volume (GTV) according to national guidelines and the visible tumor tissue (GTVT). MRI and PET based delineations were evaluated by absolute volumes and Dice similarity coefficients.

Results

The median volume of the GTVs was 27 and 31 cm3 for PET and MRI, respectively, while it was 6 and 11 cm3 for GTVT. Both GTV and GTVT volumes were highly correlated between delineators (r = 0.90 and r = 0.96, respectively). The median Dice similarity coefficient was 0.75 when comparing the GTVs based on PET/CT (GTVPET) with the GTVs based on MRI and CT (GTVMRI). The median Dice coefficient was 0.56 when comparing the visible tumor volume evaluated by PET (GTVT_PET) with the same volume evaluated by MRI (GTVT_MRI). Margins of 1–2 mm in the axial plane and 7–8 mm in superoinferior direction were required for coverage of the individual observer’s GTVs.

Conclusions

The rather good agreement between PET- and MRI-based GTVs indicates that either modality may be used for standard target delineation of anal cancer. However, larger deviations were found for GTVT, which may impact future tumor boost strategies.
Literature
1.
go back to reference Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, et al. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiother Oncol. 2014;111(3):330–9.CrossRefPubMed Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, et al. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiother Oncol. 2014;111(3):330–9.CrossRefPubMed
2.
go back to reference Bentzen AG, Balteskard L, Wanderas EH, Frykholm G, Wilsgaard T, Dahl O, et al. Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors. Acta Oncol. 2013;52(4):736–44.CrossRefPubMed Bentzen AG, Balteskard L, Wanderas EH, Frykholm G, Wilsgaard T, Dahl O, et al. Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors. Acta Oncol. 2013;52(4):736–44.CrossRefPubMed
3.
go back to reference Vuong T, Kopek N, Ducruet T, Portelance L, Faria S, Bahoric B, et al. Conformal therapy improves the therapeutic index of patients with anal canal cancer treated with combined chemotherapy and external beam radiotherapy. Int J Radiat Oncol. 2007;67(5):1394–400.CrossRef Vuong T, Kopek N, Ducruet T, Portelance L, Faria S, Bahoric B, et al. Conformal therapy improves the therapeutic index of patients with anal canal cancer treated with combined chemotherapy and external beam radiotherapy. Int J Radiat Oncol. 2007;67(5):1394–400.CrossRef
4.
go back to reference Kachnic LA, Winter K, Myerson RJ, Goodyear MD, Willins J, Esthappan J, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and Mitomycin-C for the reduction of acute morbidity in carcinoma of the Anal Canal. Int J Radiat Oncol. 2013;86(1):27–33.CrossRef Kachnic LA, Winter K, Myerson RJ, Goodyear MD, Willins J, Esthappan J, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and Mitomycin-C for the reduction of acute morbidity in carcinoma of the Anal Canal. Int J Radiat Oncol. 2013;86(1):27–33.CrossRef
5.
go back to reference Fotina I, Lutgendorf-Caucig C, Stock M, Potter R, Georg D. Critical discussion of evaluation parameters for inter-observer variability in target definition for radiation therapy. Strahlenther Onkol. 2012;188(2):160–7.CrossRefPubMed Fotina I, Lutgendorf-Caucig C, Stock M, Potter R, Georg D. Critical discussion of evaluation parameters for inter-observer variability in target definition for radiation therapy. Strahlenther Onkol. 2012;188(2):160–7.CrossRefPubMed
6.
go back to reference Ng M, Leong T, Chander S, Chu J, Kneebone A, Carroll S, et al. Australasian gastrointestinal trials group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. Int J Radiat Oncol. 2012;83(5):1455–62.CrossRef Ng M, Leong T, Chander S, Chu J, Kneebone A, Carroll S, et al. Australasian gastrointestinal trials group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. Int J Radiat Oncol. 2012;83(5):1455–62.CrossRef
7.
go back to reference Ciombor KK, Ernst RD, Brown G. Diagnosis and diagnostic imaging of Anal Canal cancer. Surg Oncol Clin N Am. 2017;26(1):45–+.CrossRefPubMed Ciombor KK, Ernst RD, Brown G. Diagnosis and diagnostic imaging of Anal Canal cancer. Surg Oncol Clin N Am. 2017;26(1):45–+.CrossRefPubMed
8.
go back to reference Jones M, Hruby G, Solomon M, Rutherford N, Martin J. The role of FDG-PET in the initial staging and response assessment of anal cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22(11):3574–81.CrossRefPubMed Jones M, Hruby G, Solomon M, Rutherford N, Martin J. The role of FDG-PET in the initial staging and response assessment of anal cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22(11):3574–81.CrossRefPubMed
9.
go back to reference Benson A, Arnoletti JP, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, et al. Anal carcinoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Ne. 2012;10(4):449–54.CrossRef Benson A, Arnoletti JP, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, et al. Anal carcinoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Ne. 2012;10(4):449–54.CrossRef
10.
go back to reference Glynne-Jones R, Tan D, Hughes R, Hoskin P. Squamous-cell carcinoma of the anus: progress in radiotherapy treatment. Nat Rev Clin Oncol. 2016;13(7):447–59.CrossRefPubMed Glynne-Jones R, Tan D, Hughes R, Hoskin P. Squamous-cell carcinoma of the anus: progress in radiotherapy treatment. Nat Rev Clin Oncol. 2016;13(7):447–59.CrossRefPubMed
11.
go back to reference Yates A, Carroll S, Kneebone A, Tse R, Horvath L, Byrne C, et al. Implementing intensity-modulated radiotherapy with simultaneous integrated boost for anal cancer: 3 year outcomes at two Sydney institutions. Clin Oncol-Uk. 2015;27(12):700–7.CrossRef Yates A, Carroll S, Kneebone A, Tse R, Horvath L, Byrne C, et al. Implementing intensity-modulated radiotherapy with simultaneous integrated boost for anal cancer: 3 year outcomes at two Sydney institutions. Clin Oncol-Uk. 2015;27(12):700–7.CrossRef
12.
go back to reference Glynne-Jones R, Renehan A. Current treatment of anal Squamous cell carcinoma. Hematol Oncol Clin N. 2012;26(6):1315–+.CrossRef Glynne-Jones R, Renehan A. Current treatment of anal Squamous cell carcinoma. Hematol Oncol Clin N. 2012;26(6):1315–+.CrossRef
13.
go back to reference Jones M, Hruby G, Stanwell P, Gallagher S, Wong K, Arm J, et al. Multiparametric MRI as an outcome predictor for anal canal cancer managed with chemoradiotherapy. BMC Cancer. 2015;15:281.CrossRefPubMedPubMedCentral Jones M, Hruby G, Stanwell P, Gallagher S, Wong K, Arm J, et al. Multiparametric MRI as an outcome predictor for anal canal cancer managed with chemoradiotherapy. BMC Cancer. 2015;15:281.CrossRefPubMedPubMedCentral
14.
go back to reference Gregoire V, Langendijk JA, Nuyts S. Advances in radiotherapy for head and neck cancer. J Clin Oncol. 2015;33(29):3277–+.CrossRefPubMed Gregoire V, Langendijk JA, Nuyts S. Advances in radiotherapy for head and neck cancer. J Clin Oncol. 2015;33(29):3277–+.CrossRefPubMed
15.
go back to reference Calais J, Thureau S, Dubray B, Modzelewski R, Thiberville L, Gardin I, et al. Areas of high F-18-FDG uptake on Preradiotherapy PET/CT identify preferential sites of local relapse after Chemoradiotherapy for non-small cell lung cancer. J Nucl Med. 2015;56(2):196–203.CrossRefPubMed Calais J, Thureau S, Dubray B, Modzelewski R, Thiberville L, Gardin I, et al. Areas of high F-18-FDG uptake on Preradiotherapy PET/CT identify preferential sites of local relapse after Chemoradiotherapy for non-small cell lung cancer. J Nucl Med. 2015;56(2):196–203.CrossRefPubMed
16.
go back to reference Heukelom J, Hamming O, Bartelink H, Hoebers F, Giralt J, Herlestam T, et al. Adaptive and innovative radiation treatment FOR improving cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer. BMC Cancer. 2013;13:84.CrossRefPubMedPubMedCentral Heukelom J, Hamming O, Bartelink H, Hoebers F, Giralt J, Herlestam T, et al. Adaptive and innovative radiation treatment FOR improving cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer. BMC Cancer. 2013;13:84.CrossRefPubMedPubMedCentral
17.
go back to reference van Elmpt W, De Ruysscher D, van der Salm A, Lakeman A, van der Stoep J, Emans D, et al. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. Radiother Oncol. 2012;104(1):67–71.CrossRefPubMed van Elmpt W, De Ruysscher D, van der Salm A, Lakeman A, van der Stoep J, Emans D, et al. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. Radiother Oncol. 2012;104(1):67–71.CrossRefPubMed
18.
go back to reference Leon O, Guren MG, Radu C, Gunnlaugsson A, Johnsson A. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. Eur J Cancer. 2015;51(18):2740–6.CrossRefPubMed Leon O, Guren MG, Radu C, Gunnlaugsson A, Johnsson A. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. Eur J Cancer. 2015;51(18):2740–6.CrossRefPubMed
19.
go back to reference Glynne-Jones R, Goh V, Agarwal A, Maher H, Dubash S, Hughes R. Anal carcinoma. In: Grosu A, Nieder C, editors. Target volume definition in radiation oncology. Heidelberg: Springer-Verlag; 2015. p. 194–216. Glynne-Jones R, Goh V, Agarwal A, Maher H, Dubash S, Hughes R. Anal carcinoma. In: Grosu A, Nieder C, editors. Target volume definition in radiation oncology. Heidelberg: Springer-Verlag; 2015. p. 194–216.
20.
go back to reference Roels S, Slagmolen P, Nuyts J, Lee JA, Loeckx D, Maes F, et al. Biological image-guided radiotherapy in rectal cancer: challenges and pitfalls. Int J Radiat Oncol. 2009;75(3):782–90.CrossRef Roels S, Slagmolen P, Nuyts J, Lee JA, Loeckx D, Maes F, et al. Biological image-guided radiotherapy in rectal cancer: challenges and pitfalls. Int J Radiat Oncol. 2009;75(3):782–90.CrossRef
21.
go back to reference Braendengen M, Hansson K, Radu C, Siegbahn A, Jacobsson H, Glimelius B. Delineation of gross tumor volume (Gtv) for radiation treatment planning of locally advanced rectal cancer using information from Mri or Fdg-pet/ct: a prospective study. Int J Radiat Oncol. 2011;81(4):E439–E45.CrossRef Braendengen M, Hansson K, Radu C, Siegbahn A, Jacobsson H, Glimelius B. Delineation of gross tumor volume (Gtv) for radiation treatment planning of locally advanced rectal cancer using information from Mri or Fdg-pet/ct: a prospective study. Int J Radiat Oncol. 2011;81(4):E439–E45.CrossRef
22.
go back to reference Shali SM, Schmitt V, Behrendt FF, Winz OH, Heinzel A, Mottaghy FM, et al. Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival. Eur J Radiol. 2016;85(8):1390–4.CrossRef Shali SM, Schmitt V, Behrendt FF, Winz OH, Heinzel A, Mottaghy FM, et al. Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival. Eur J Radiol. 2016;85(8):1390–4.CrossRef
23.
go back to reference Peulen H, Belderbos J, Guckenberger M, Hope A, Grills I, van Herk M, et al. Target delineation variability and corresponding margins of peripheral early stage NSCLC treated with stereotactic body radiotherapy. Radiother Oncol. 2015;114(3):361–6.CrossRefPubMed Peulen H, Belderbos J, Guckenberger M, Hope A, Grills I, van Herk M, et al. Target delineation variability and corresponding margins of peripheral early stage NSCLC treated with stereotactic body radiotherapy. Radiother Oncol. 2015;114(3):361–6.CrossRefPubMed
24.
go back to reference Nijkamp J, Swellengrebel M, Hollmann B, de Jong R, Marijnen C, van Vliet-Vroegindeweij C, et al. Repeat CT assessed CTV variation and PTV margins for short- and long-course pre-operative RT of rectal cancer. Radiother Oncol. 2012;102(3):399–405.CrossRefPubMed Nijkamp J, Swellengrebel M, Hollmann B, de Jong R, Marijnen C, van Vliet-Vroegindeweij C, et al. Repeat CT assessed CTV variation and PTV margins for short- and long-course pre-operative RT of rectal cancer. Radiother Oncol. 2012;102(3):399–405.CrossRefPubMed
25.
go back to reference Krengli M, Milia ME, Turri L, Mones E, Bassi MC, Cannillo B, et al. FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma. Radiat Oncol. 2010;5:10.CrossRefPubMedPubMedCentral Krengli M, Milia ME, Turri L, Mones E, Bassi MC, Cannillo B, et al. FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma. Radiat Oncol. 2010;5:10.CrossRefPubMedPubMedCentral
26.
go back to reference Anderson C, Koshy M, Staley C, Esiashvili N, Ghavidel S, Fowler Z, et al. PET-CT fusion in radiation management of patients with anorectal tumors. Int J Radiat Oncol Biol Phys. 2007;69(1):155–62.CrossRefPubMed Anderson C, Koshy M, Staley C, Esiashvili N, Ghavidel S, Fowler Z, et al. PET-CT fusion in radiation management of patients with anorectal tumors. Int J Radiat Oncol Biol Phys. 2007;69(1):155–62.CrossRefPubMed
27.
go back to reference Bannas P, Weber C, Adam G, Frenzel T, Derlin T, Mester J, et al. Contrast-enhanced [(18)F]fluorodeoxyglucose-positron emission tomography/computed tomography for staging and radiotherapy planning in patients with anal cancer. Int J Radiat Oncol Biol Phys. 2011;81(2):445–51.CrossRefPubMed Bannas P, Weber C, Adam G, Frenzel T, Derlin T, Mester J, et al. Contrast-enhanced [(18)F]fluorodeoxyglucose-positron emission tomography/computed tomography for staging and radiotherapy planning in patients with anal cancer. Int J Radiat Oncol Biol Phys. 2011;81(2):445–51.CrossRefPubMed
28.
go back to reference Patel DA, Chang ST, Goodman KA, Quon A, Thorndyke B, Gambhir SS, et al. Impact of integrated PET/CT on variability of target volume delineation in rectal cancer. Technol Cancer Res T. 2007;6(1):31–6.CrossRef Patel DA, Chang ST, Goodman KA, Quon A, Thorndyke B, Gambhir SS, et al. Impact of integrated PET/CT on variability of target volume delineation in rectal cancer. Technol Cancer Res T. 2007;6(1):31–6.CrossRef
29.
go back to reference Buijsen J, van den Bogaard J, van der Weide H, Engelsman S, van Stiphout R, Janssen M, et al. FDG-PET-CT reduces the interobserver variability in rectal tumor delineation. Radiother Oncol. 2012;102(3):371–6.CrossRefPubMed Buijsen J, van den Bogaard J, van der Weide H, Engelsman S, van Stiphout R, Janssen M, et al. FDG-PET-CT reduces the interobserver variability in rectal tumor delineation. Radiother Oncol. 2012;102(3):371–6.CrossRefPubMed
Metadata
Title
Target volume delineation of anal cancer based on magnetic resonance imaging or positron emission tomography
Authors
Espen Rusten
Bernt Louni Rekstad
Christine Undseth
Ghazwan Al-Haidari
Bettina Hanekamp
Eivor Hernes
Taran Paulsen Hellebust
Eirik Malinen
Marianne Grønlie Guren
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2017
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-017-0883-z

Other articles of this Issue 1/2017

Radiation Oncology 1/2017 Go to the issue